Hutchison China MediTech Priced, Nasdaq: HCM

CK Hutchison-backed pharmaceutical with a pipeline of oncology candidates.

Industry: Health Care

Latest Trade: $19.82 0.00 (0.0%)

First Day Return: -0.7%

Return from IPO: +46.8%

Industry: Health Care

We are an innovative biopharmaceutical company based in China aiming to become a global leader in the discovery, development and commercialization of targeted therapies for oncology and immunological diseases. We have created a broad portfolio of drug candidates targeting eight molecular targets. We have taken a chemistry-focused approach to develop highly selective small molecule tyrosine kinase inhibitors that are intended to have potentially global best-in-class efficacy and are deliberately engineered to improve drug exposure, reduce known class-related toxicities and allow different drug therapies to be combinable.
more less
IPO News for Hutchison China MediTech
more
IPO Data
IPO File Date 10/16/2015
Offer Price $13.50
Price Range $13.50 - $13.50
Offer Shares (mm) 7.5
Deal Size ($mm) $101
IPO Data
IPO Date 03/16/2016
Offer Price $13.50
Price Range $13.50 - $13.50
Offer Shares (mm) 7.5
Deal Size ($mm) $101
Underwriters
more
Company Data
Headquarters Hong Kong, Hong Kong
Founded 2000
Employees 475
Website www.chi-med.com